Navigation Links
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Date:3/12/2009

data evaluating the safety and performance of a bioabsorbable drug eluting coronary stent out to two years. Abbott's bioabsorbable everolimus eluting coronary device is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore blood flow by propping a clogged vessel open, and to provide support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable device is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott has consistently been at the forefront of advances in interventional cardiology - from the early days of angioplasty to our continued success with bare metal stents and the market-leading XIENCE V drug eluting stent. Our bioabsorbable device is another example of scientific innovation leading to an interventional breakthrough," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Today's data publication in The Lancet confirms the promise our bioabsorbable device holds as a vasorestorative therapy for patients with coronary artery disease."

Abbott will begin enrolling patients in the second phase of its international ABSORB clinical trial in the first half of 2009.

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 110 patients in Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days, six, nine and 18 months, and one and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the sten
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
4. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
8. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
9. SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
10. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
11. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
(Date:8/29/2014)... BOSTON , Aug. 29, 2014   Vittamed Corporation ... Boston announced today that T. (Teo) Forcht ... to the company,s Board of Directors. " ... distinguished career in neurosurgery, medical innovation and venture capital," said ... are extremely delighted to add his clinical, strategic, and entrepreneurial ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" or ... today that it intends to release its financial results ... June 30, 2014 after market trading ends on Tuesday, ... a conference call for 4:30 p.m. U.S. EDT on ... 6:30 a.m. AEST), to review the Company,s financial results, commercial ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... healthcare organizations, acquired a new medical center from LAXMed. The ... airport and less than 2 miles west of the 405 ... center within Southern California. The new LAX center is located ... 90045. , The new Healthpointe LAX office ...
(Date:8/29/2014)... 2014 - Despite US Preventive Services Task Force recommendations ... several of which may be ameliorated through technological approaches ... Langone Medical Center published online August 21, 2014 in ... JGIM ). , David Levine, MD, MA, a third ... NYU Langone, and colleagues found that compared to usual ...
(Date:8/29/2014)... August 29, 2014 Today, Gen. Arthur ... Coalitions of America (CADCA) , the nation’s leading substance ... to President Obama’s intent to nominate Michael Botticelli as ... strongly supports President Obama’s decision to nominate Michael Botticelli ... ideal person to hold this important position at this ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
Breaking Medicine News(10 mins):Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:CADCA Statement on Nomination of Michael Botticelli as U.S. Drug Czar 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
... , SATURDAY, Jan. 7 (HealthDay News) -- If you exercise ... stay safe, an expert advises. The main issue is hypothermia, ... Bryant, chief science officer at the American Council on Exercise. ... to control your body heat while exercising. A hat or helmet ...
... In a new review of imaging studies spanning more ... positron emission tomography (PET) safely and accurately detects dementia, ... elderly, Alzheimer,s disease. This research is featured in the ... . Researchers reviewed numerous PET studies to ...
... , FRIDAY, Jan. 6 (HealthDay News) -- Air ... high blood pressure in black American women, a new study ... the chances of acute cardiovascular events such as stroke and ... increases the likelihood of chronic diseases such as diabetes and ...
... HealthDay Reporter , FRIDAY, Jan. 6 (HealthDay News) -- ... have a different type of disease than those with more ... for them, new research suggests. "We are beginning to ... mechanisms," said Dr. John Fahy, director of the Airway Clinical ...
... the January issue of the Journal of the ... dose optimization in pediatric computed tomography (CT) scans. Approximately ... various pediatric clinical indications per year in the United ... most important aspect of reducing radiation dose with CT ...
... 6 (HealthDay News) -- Diabetes patients require continuous health ... study concludes. For the study, U.S. researchers analyzed ... care between 2005 and 2007 at 50 federally qualified ... reduced-cost care is provided to low-income patients whether they ...
Cached Medicine News:Health News:Safety Tips for Cold-Weather Exercise 2Health News:A decade of research proves PET effectively detects dementia 2Health News:A decade of research proves PET effectively detects dementia 3Health News:Smog Tied to Raised Risk of Chronic Illness in Black Women 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 3Health News:Experts offer pointers for optimizing radiation dose in pediatric CT 2Health News:Diabetes Care Thwarted by Unstable Health Insurance: Study 2
... The IMMULITE 2000, a continuous ... throughput of 200 tests per hour, ... efficiency and consolidation in medium- and ... package, with its self-explanatory graphical user ...
AIA - Nex.IA immunoassay analyzer state of the art automation and flexibility for high throughput immunoassay testing...
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros 950 provides ... the needs of high volume ... of up to 900 results ... can store and perform the ...
Medicine Products: